Specifically, glucose control, total daily insulin dose (TDD), body mass (BM), insulin resistance, blood pressure (BP), serum triacylglycerols (TAG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and diabetes treatment satisfaction were examined at 6 and 12 months post-CSII-start in patients with T2D. This evidence concerns the gene INS and diabetes mellitus.